Everolimus for Advanced Pancreatic Neuroendocrine Tumors | Zendy

James C. Yao | Zendy; Manisha H. Shah | Zendy; Tetsuhide Ito | Zendy; C. Lombard Bohas | Zendy; Edward M. Wolin | Zendy; Eric Van Cutsem | Zendy; Timothy J. Hobday | Zendy; Takuji Okusaka | Zendy; Jaume Capdevila | Zendy; Elisabeth G.E. de Vries | Zendy; Paola Tomassetti | Zendy; Marianne Pavel | Zendy; Sakina Hoosen | Zendy; T Haas | Zendy; Jeremie Lincy | Zendy; David Lebwohl | Zendy; Kjell Öberg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

Author(s) -

James C. Yao,

Manisha H. Shah,

Tetsuhide Ito,

C. Lombard Bohas,

Edward M. Wolin,

Eric Van Cutsem,

Timothy J. Hobday,

Takuji Okusaka,

Jaume Capdevila,

Elisabeth G.E. de Vries,

Paola Tomassetti,

Marianne Pavel,

Sakina Hoosen,

T Haas,

Jeremie Lincy,

David Lebwohl,

Kjell Öberg

Publication year - 2011

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1009290

Subject(s) - everolimus , medicine , neuroendocrine tumors , placebo , hazard ratio , clinical endpoint , adverse effect , gastroenterology , progression free survival , randomized controlled trial , surgery , confidence interval , oncology , chemotherapy , pathology , alternative medicine

Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two phase 2 studies. We evaluated the agent in a prospective, randomized, phase 3 study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research